Serum and synovial fluid levels of tumor necrosis factor-like ligand 1A and decoy receptor 3 in rheumatoid arthritis

Cytokine. 2015 Apr;72(2):185-9. doi: 10.1016/j.cyto.2014.12.026. Epub 2015 Jan 31.

Abstract

Objective: To measure the levels of Tumor necrosis factor (TNF)-like ligand 1A (TL1A) and decoy receptor 3 (DcR3) in serum and synovial fluid (SF) of patients with rheumatoid arthritis (RA). To evaluate the effect of recombinant human (rh) TL1A on interleukin (IL)-17 production and IL-17mRNA expression.

Methods: The serum and SF levels of TL1A and DcR3, and the production of IL-17 by rhTL1A-treated PBMC were measured by enzyme-linked immunosorbent assay (ELISA). The expression of IL-17 mRNA by rhTL1A-treated PBMC was measured by real-time reverse transcriptase polymerase chain reaction (RT-PCR). We also tested the change of TL1A and DcR3 level following TNF-α blockade therapy.

Results: Serum TL1A and DcR3 levels were higher in RA patients. This increase was more significant in RF and anti-CCP positive patients. TL1A and DcR3 levels were higher in SF samples than in paired sera. TL1A and DcR3 decreased after anti-TNF treatment. rhTL1A increased the production of IL-17 protein and the expression of IL-17mRNA.

Conclusion: TL1A and DcR3 may be of pathogenic and potentially of therapeutic importance in RA patients.

Keywords: Decoy receptor 3; Interleukin-17; Rheumatoid arthritis; Tumor necrosis factor-like ligand 1A.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Anti-Inflammatory Agents, Non-Steroidal
  • Arthritis, Rheumatoid / immunology*
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Humans
  • Infliximab / administration & dosage
  • Infliximab / therapeutic use
  • Interleukin-17 / genetics
  • Interleukin-17 / immunology
  • Leukocytes, Mononuclear / immunology
  • Leukocytes, Mononuclear / metabolism
  • Male
  • Middle Aged
  • Real-Time Polymerase Chain Reaction
  • Receptors, Tumor Necrosis Factor, Member 6b / blood
  • Receptors, Tumor Necrosis Factor, Member 6b / metabolism*
  • Synovial Fluid / immunology*
  • Tumor Necrosis Factor Ligand Superfamily Member 15 / blood
  • Tumor Necrosis Factor Ligand Superfamily Member 15 / metabolism*
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Interleukin-17
  • Receptors, Tumor Necrosis Factor, Member 6b
  • TNFRSF6B protein, human
  • Tumor Necrosis Factor Ligand Superfamily Member 15
  • Tumor Necrosis Factor-alpha
  • Infliximab